RVL Pharmaceuticals plc (NASDAQ:RVLP) finished Wednesday with an addition of $0.02 to close at $0.16, an upside of 16.88 percent. An average of 2,884,480 shares of common stock have been traded in the last five days. There was a fall of -$0.0429 in the past week, and it reached a new high 7 times over the past 12 months. The last 20 days have seen an average of 931,640 shares traded, while the 50-day average volume stands at 446,204.
RVLP stock has decreased by -58.03% in the last month. The company shares reached their 1-month lowest point of $0.1300 on 08/22/23. With the stock rallying to its 52-week high on 03/20/23, shares of the company touched a low of $0.13 and a high of $2.99 in 52 weeks. It has reached a new high 14 times so far this year and lost -85.35% or -$0.9559 in price. In spite of this, the price is down -94.51% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
RVL Pharmaceuticals plc (RVLP) stock’s beta is 1.11. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 0.43, the price-to-book (PB) ratio at 1.03.
Financial Health
The quick ratio of RVL Pharmaceuticals plc for the three months ended June 30 was 0.40, and the current ratio was 0.40, indicating that the company is not able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 3.55 for the quarter ending June 30. RVL Pharmaceuticals plc’s EBITDA margin for the year ending June 30 is -91.32%. Its gross profit as reported stood at $40.27 million compared to revenue of $49.72 million.
Earnings Surprise
In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$23.89 million in the quarter, while revenues of -$11.61 million were grew 49.31%. The analyst consensus anticipated RVL Pharmaceuticals plc’s latest quarter earnings to come in at -$0.11 per share, but it turned out to be -$0.24, a -118.20% surprise. For the quarter, EBITDA amounted to -$8.03 million. Shareholders own equity worth $99.53 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at RVL Pharmaceuticals plc (RVLP) price momentum. RSI 9-day as of the close on 23 August was 24.45%, suggesting the stock is oversold, with historical volatility in this time frame at 356.60%.
As of today, RVLP’s price is $0.1660 -20.72% or -$0.0429 from its 5-day moving average. RVLP is currently trading -62.69% lower than its 20-day SMA and -85.85% lower than its 100-day SMA. However, the stock’s current price level is -81.25% below the SMA50 and -90.11% below the SMA200.
The stochastic %K and %D were 4.16% and 2.56%, respectively, and the average true range (ATR) was 0.0574. With the 14-day stochastic at 9.22% and the average true range at 0.0580, the RSI (14) stands at 26.62%. The stock has reached -0.1015 on the 9-day MACD Oscillator while the 14-day reading was at -0.1827.
Analyst Ratings
The consensus rating for RVL Pharmaceuticals plc (RVLP) among analysts is Overweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell RVLP, while 1 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 1 analysts, while 2 others rate it as a “buy”.
What is RVLP’s price target for the next 12 months?
Analysts predict a range of price targets between $1.00 and $6.00, with a median target of $2.00. Taking a look at these predictions, the average price target given by analysts for RVL Pharmaceuticals plc (RVLP) stock is $2.72.
